US pharma giant Merck & Co today announced positive results from the Phase III STRIDE-13 trial evaluating Capvaxive ...

UK government-backed agency the Medicines Discovery Catapult (MDC) and Crown Bioscience have formed a strategic global ...

Boston, USA-based clinical-stage biopharma Odyssey Therapeutics announced the closing of a $213 million Series D financing.

The Inflation Reduction Act has rewritten the rules of US drug economics. Negotiated prices and a Part D redesign have ...

Precision for Medicine, a next-generation provider of drug research and development services, today announced that Dr ...

Danish CNS specialist Lundbeck is flexing its muscles in the competitive migraine space with a comprehensive collection of ...

The Trump administration has announced its intent to levy tariffs on pharmaceutical products and proposed lowering drug ...

Despite recent declines, opioids remain commonly prescribed to about one in five \us adults who live with chronic pain as ...

US drugmaker Merck & Co, known as MSD outside of North America, has scrapped a £1 billion ($1.35 billion) research center in ...

Following on from the San Francisco-based firm’s attempts to sell compounded GLP-1 agonists to the weight loss market—whether ...

The Trump administration is weighing a draft executive order that could block the import of Chinese-made experimental ...

A new analysis from Phesi of 583 recruiting clinical trials or trials about to start involving GLP-1 receptor antagonists ...